Report Company Directory

Relmada Therapeutics Inc

• Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology by GlobeNewsWire
• Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates by GlobeNewsWire
• Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025 by GlobeNewsWire
• Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants by GlobeNewsWire
• Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer by GlobeNewsWire
• Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 by GlobeNewsWire
• Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement by GlobeNewsWire
• Relmada Issues Mid-Year CEO Letter to Shareholders by GlobeNewsWire
• Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC by GlobeNewsWire
• Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 by GlobeNewsWire

Relo Group Inc.

• 2Q FY3/26 results: OP down YoY, but likely in line with guidance by Mizuho Securities
• 26/3期2Q決算：前期比で営業減益も、会社計画はインラインと考える by Mizuho Securities
• Lowering our investment rating on uncertain operating conditions by Mizuho Securities
• 事業環境の不透明感から投資判断引き下げ by Mizuho Securities
• 1Q FY3/26 results: profits down on delayed property sales, but KPIs are solid by Mizuho Securities
• 26/3期1Q決算：物件売却の期ずれ等から減益スタートも､KPIは堅調 by Mizuho Securities
• We expect stable annualized profit growth of just under 10% from FY3/27 onward by Mizuho Securities
• 来期以降は年率10%弱の安定増益へ by Mizuho Securities
• FY3/25 results: new MTP slightly disappointing by Mizuho Securities
• 25/3期決算：新中計はやや物足りない印象 by Mizuho Securities

Relpol S.A.

• Relpol S.A.: 1 director by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research

RELSTRUCT BUILDCON LTD

RELX NV

• Coffee, Croissants & Credit/Equinix, RELX, Telecom Italia, Orange, Verizon, Klepierre and Gecina by ING Financial Markets
• Coffee, Croissants & Credit/Relx upgraded, Credit spreads marginally tighter by ING Financial Markets
• Coffee, Croissants & Credit/Enel, Iberdrola, Telefonica, and RELX by ING Financial Markets
• Benelux TMT sector/When dull becomes exciting by ING Financial Markets
• RELX/Solid cash generation continues by ING Financial Markets
• Coffee, Croissants & Credit/Dutch utilities, Orange, RELX and Telenet by ING Financial Markets
• Coffee, Croissants & Credit/Nestlé, Carrefour, RELX by ING Financial Markets
• Morning Note: AKZA NA, ASM NA, BAR BB, BFIT NA, BCART BB, PROX BB, REL LN, SIP BB, SLIGR NA by KBC Securities
• Coffee, Croissants & Credit/Credit overshoots, Pernod Ricard, Unilever, Metro, Telenet, RELX by ING Financial Markets
• Morning Note: BPOST BB, DIE BB, REL LN, TESB BB by KBC Securities